Evidence map›Paper›PMID 36313216›Full record

ReviewSynthetic and systems biotechnology2023

Heparin mimetics as potential intervention for COVID-19 and their bio-manufacturing.

Lan Jiang, Tianji Zhang, Hongzhong Lu, Saijuan Li, Kangjie Lv, Alex Tuffour, Lixin Zhang, Kan Ding, Jin-Ping Li, Hongmei Li and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Synthetic and systems biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lan JiangDepartment of Cardiothoracic Surgery, Children's Hospital of Nanjing Medical University, Nanjing, 210093, China.
Tianji ZhangDivision of Chemistry and Analytical Science, Key Laboratory of Chemical Metrology and Applications on Nutrition and Health for State Market Regulation, National Institute of Metrology, Beijing, 100029, China.
Hongzhong LuState Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China.
Saijuan LiGlycochemistry & Glycobiology Lab, Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Kangjie LvState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Alex TuffourState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Lixin ZhangState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.
Kan DingGlycochemistry & Glycobiology Lab, Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Jin-Ping LiInternational Research Center for Soft Matter, Beijing University of Chemical Technology, Beijing, 100029, China.
Hongmei LiDivision of Chemistry and Analytical Science, Key Laboratory of Chemical Metrology and Applications on Nutrition and Health for State Market Regulation, National Institute of Metrology, Beijing, 100029, China.
Xueting LiuState Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has caused severe health problems worldwide and unprecedented decimation of the global economy. Moreover, after more than 2 years, many populations are still under pressure of infection. Thus, a broader perspective in developing antiviral strategies is still of great importance. Inspired by the observed multiple benefits of heparin in the treatment of thrombosis, the potential of low molecular weight heparin (LMWH) for the treatment of COVID-19 have been explored. Clinical applications found that LMWH decreased the level of inflammatory cytokines in COVID-19 patients, accordingly reducing lethality. Furthermore, several

Indexed as

Biological activitiesBio-productionBiosynthesisHeparin

Identifiers

PMID36313216
PMCPMC9595387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.